Skip to main content
Premium Trial:

Request an Annual Quote

Aaron Kantor, Frank Torti

Premium
The Immune Tolerance Institute this week said Aaron Kantor joined the company as chief scientific officer.
 
Prior to ITI, Kantor was executive director of cell and molecular biology for biomarker discovery sciences at Pharmaceutical Product Development, a contract research organization. Before that, he was manager for the rare cell program and cell depletion therapeutic program at AmCell.
 

 
The US Food and Drug Administration named Frank Torti its first chief scientist this week. He also was named the agency’s principal deputy commissioner.
 
Torti will support the launch of the FDA Fellowship Program to attract professionals from various disciplines for a two-year training program. “The new office will work to ensure the quality and regulatory focus of the intramural research programs of the agency, and place special emphasis on the importance of clinical research trials that are a part of the foundation of the FDA’s regulatory structure,” the FDA said in a statement.
 
Torti is the Charles L. Spurr Professor of Medicine, chair of the department of cancer biology, and director of the Comprehensive Cancer Center at the Wake Forest University School of Medicine.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.